Abstract. The tumor suppressor gene PATCHED1 (PTCH1) is a member of the hedgehog signaling pathway and causatively associated with several human sporadic and familial cancers, including those of the skin, muscle and brain. Inactivation of one Ptch1 allele in the mouse results in the development of medulloblastoma and rhabdomyosarcoma (RMS), the latter being a malignant tumor of skeletal muscle origin. To identify genes involved in the pathogenesis of Ptch1-associated RMS, we have monitored the expression of 588 genes in RMS and normal skeletal muscle (SM) of heterozygous Ptch1 neo67/+ mice using cDNA array technology. RMS displayed increased transcript levels of several genes such as transforming growth factor-ß1 (Tgfb1), insulin-like growth factor 2 (Igf2), villin 2 (Vil2), integrin ß1 (Itgb1), Sloan-Kettering viral oncogene homolog (Ski), and insulinlike growth factor binding protein 3 (Igfbp3), as well as numerous genes coding for structural components of myogenic cells such as myosin light polypeptide 4 (Myl4), myosin light polypeptide 6 (Myl6), and vimentin (Vim). Detailed promoter analysis revealed a putative Gli binding site in the second promoter region (P2) of the murine Tgfb1 gene. However, using reporter assay we show that the P2 promoter is not responsive to hedgehog signaling. We furthermore describe that Tgfb1 expression could not be activated in C2C12 myoblasts in the presence of murine Shh-N peptide and that Tgfb1 is equally expressed in both wild-type and Ptch1-deficient mouse embryos. In line with this, TGFB1 was strongly expressed in human RMS cell lines independently of the GLI1 expression status. In summary, our results suggest that aberrant expression of Tgfb1 may be involved in RMS development in a way that is independent of hedgehog signaling.
Introduction
RMS is the most common soft-tissue sarcoma in children, representing approximately 9% of pediatric solid cancers (1) . This tumor is thought to arise as a consequence of regulatory disruption of skeletal muscle progenitor cell growth and differentiation, yet the precise cell of origin is not entirely clear (2) . The two major histopathological classifications of RMS, the embryonal form (ERMS) and the rarer alveolar form (ARMS), are described to distinguish the two types not only regarding their histology and their degree of differentiation, but also their prognosis (3) . A recent study has reported estimated 3-year failure-free survival rates of 66 and 83% for ARMS and ERMS, respectively (4) . It has furthermore been demonstrated that both subtypes are distinguishable based on the detection of distinct genetic markers (5) . ERMS is generally characterized by the loss of heterozygosity at the chromosomal band 11p15 (6), a region which harbors the imprinted genes IGF2 and H19. In contrast, the majority of ARMS are reported to have the characteristic reciprocal translocations t(2;13)(p35;q14) and t(1;13)(p36;q14), giving rise to PAX3-and PAX7-FKHR fusion proteins, respectively (7, 8) . Common to all tumors is their positive immunochemical staining for certain skeletal muscle structural proteins, such as alpha actin, fast myosin, myosin heavy chain as well as certain proteins not specific for muscle as desmin and vimentin (9, 10) .
Coupled with the relative rarity of this tumor, various mouse model systems for RMS have been developed which allow for the investigation of the molecular mechanisms underlying tumorigenesis of RMS and the delineation of novel targets that may be important in developing new therapeutic strategies for the treatment of RMS. One important RMS mouse model was introduced by Hahn and colleagues in 1998 (11) , in which mice bearing only one functional Ptch1 allele develop neoplasms resembling human embryonal RMS on both histological and molecular levels (12) (13) (14) . The human homologue of the Drosophila segment polarity gene PTCH1 encodes an inhibitory component of the receptor complex of the hedgehog signaling pathway, which is implicated in a variety of human cancers (15, 16) . Mutations of PTCH1 were first described in patients of the nevoid basal cell carcinoma syndrome or Gorlin syndrome (17, 18) . These patients are predisposed to a range of neoplasias including basal cell carcinoma, medulloblastoma, and RMS (19) . Even though subsequent studies have shown PTCH1 mutations in sporadic forms of basal cell carcinoma and medulloblastoma (15) , PTCH1 mutations in sporadic RMS are relatively rare (20) . However, overexpression of the hedgehog target genes PTCH1 and GLI1 at the mRNA level has recently been reported in nearly all cases of sporadic rhabdomyoma and RMS, indicating an active hedgehog signaling pathway (21) .
The cDNA microarray technology (22) provides a unique opportunity to simultaneously monitor the expression of thousands of genes and has been successfully applied to almost all of the main human cancers including leukemia (23) , lymphoma (24) , adenocarcinoma of the lung (25) , breast (26) and prostate (27) . To provide new insights into molecular mechanisms by which RMS arise, we have monitored the gene expression of 588 genes in RMS of heterozygous Ptch1 neo67/+ mice using the cDNA array technology. Our gene expression profiling approach has led to the identification of Tgfb1 as a highly expressed gene in RMS of the Ptch1 mouse model. Moreover, our observations suggest that aberrant expression of the Tgfb1 gene may be involved in the development of RMS independently of hedgehog signaling.
Materials and methods
Tissue specimens. Rhabdomyosarcoma (RMS) and normal skeletal muscle (SM) as a reference were excised from heterozygous Ptch1 neo67/+ mice maintained on a CD1 background (11), immediately frozen in liquid nitrogen and stored at -80˚C. Tumors were collected with consideration of all necessary legal requirements. Histological analysis of 5 μm hematoxylin/eosin stained tumor sections was carried out by a pathologist. Only RMS tissues containing >90% tumor cells were used in this study. E9.5 Ptch1 +/+ and Ptch1
embryos from cross-bred Ptch1 neo67/+ mice were isolated and genotyped as previously described (11) .
Tumor cell lines. RMS cell lines (RH-1, RH-30, RMS-13, and RD) and the A673 Ewing sarcoma cell line were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) and American Type Culture Collection (ATCC, Manassas, VA). Cells were maintained as the suppliers recommended.
RNA extraction. E9.5 embryos of the same Ptch1 genotype were pooled and total RNA was prepared in TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. In the same way total RNA was extracted from tumor and reference tissue as well as tumor cell lines. For cDNA array experiments, total RNA was treated with DNase (Roche Diagnostics, Mannheim, Germany) and poly(A) RNA was prepared using the mRNA Oligotex Kit (Qiagen, Hilden, Germany).
cDNA array hybridization. We used an ATLAS mouse cDNA expression array containing 588 gene specific cDNAs spotted in duplicate on a nylon membrane, which also includes cDNAs corresponding to housekeeping genes and negative controls (Clontech, Palo Alto, CA). Poly(A) RNA of RMS and SM tissue (1 μg) was converted into labeled cDNA probe by using gene specific primers and 32 P-dATP according to the recommendation of the manufacturer (Clontech). Unincorporated nucleotides were removed from labeled cDNA with MicroSpin G-50 columns (Pharmacia, Freiburg, Germany). Hybridization and stringency washes were carried out according to the manufacturer's instructions (Clontech). Hybridized membranes were exposed for 24 h to imaging plates BAS-III S (Fuji Photo Film, Tokyo, Japan) and digital images were captured using a FUJIX BAS1000 phosphor imager (Fuji Photo Film). Data acquisition by densitometric scanning was then performed with the PCBAS 2.09 g software (Raytest, Straubenhardt, Germany). Signal intensities were corrected for local background and normalized to the housekeeping gene Gapdh. Expression of this gene emerged similar in RMS and SM tissues of Ptch1 neo67/+ mice, as previously described (14) . Data analysis was performed including only genes whose expression was altered in both experiments at least 2-fold between RMS and the corresponding SM tissue.
Northern hybridization. For Northern blot hybridization, 10 μg of total RNA were size fractioned, transferred to a nylon membrane and hybridized according to standard protocols (28) . Probe labeling was performed using the Prime-It RmT kit (Stratagene, La Jolla, CA). Probes for the mouse Table I . Gene-specific primers used for RT-PCR.
Igfbp3 and Tgfb1 genes were released from IMAGE clones AA990365 and AA821506, respectively (RZPD, Berlin, Germany). The Igf2 probe was described previously (11) . The remaining murine DNA probes were generated from total RNA isolated from mouse embryo by RT-PCR using primers as given in Table I . Probes for the human GLI1, TGFB1 and GAPDH genes were generated by insert release from IMAGE clones AI473373, AI304490 and BF338366, respectively (RZPD). All probes used were sequence verified prior to hybridization using an ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA) and an ABI PRISM 377 DNA Sequencer (Applied Biosystems).
Sonic hedgehog stimulation. C2C12 myoblasts were obtained from ATCC and maintained as the supplier recommended. For sonic hedgehog (Shh) stimulation experiments, cells were grown in DMEM containing 10% FCS in 6-well plates to 90% confluency and then changed to low serum medium (DMEM with 0.5% FCS) containing 1 μg/ml recombinant mouse Shh amino-terminal peptide (Shh-N; R&D Systems, Minneapolis, MN) or Shh-N vehicle (0.1% BSA/PBS). For the inhibition of hedgehog signaling, cells were additionally exposed to 3-keto-N-aminoethyl aminocaproyl dihydrocinnamoyl cyclopamine (Toronto Research Chemicals, Toronto, Canada) in a final concentration of 1 μM. Total RNA was isolated after indicated times using TRIzol (Invitrogen) as described by the supplier.
Semi-quantitative reverse transcription-PCR.
Reverse transcription of total RNA was performed using random hexamers (Roche Diagnostics) and SuperScriptII reverse transcriptase (Invitrogen). PCR amplifications of the genes Gli1, Tgfb1, and Gapdh were carried out with 50 ng of cDNA, 200 nM forward primer and reverse primer (Table I) in a 20 μl final reaction mixture for 25 (Gapdh) and 28 cycles (Gli1 and Tgfb1) consisting of 30 sec denaturation at 95˚C, hybridization of primers for 30 sec at 55˚C and extension for 1 min at 72˚C. Amplification of Gapdh as an endogenous control was performed to standardize the amount of sample RNA. Digital images of PCR fragments were captured using the PCBAS 2.09 g software (Raytest).
Reporter assays. The 5'-untranslated leader sequence of the murine Tgfb1 gene from the first transcription initiation site up to the translational initiation codon (29) was PCR amplified using the IMAGE clone BU511657 (RZPD) as a template and Tgfb1 forward (5'-CTGCCTCGAGTCGCGCCCAGG CCGTCCCCCTCCTC-3') and reverse (5'-CTGCCCATGG GGGAGGCGGCGCCCCACGGCA-3') primers with XhoI and NcoI overhangs (underlined), respectively. The 849 bp PCR fragment containing the P2 promoter and the putative Gli1 binding site was cloned into the XhoI and NcoI sites of the pGL3 basic firefly luciferase plasmid (Promega, Madison, WI) to produce pGL3-Tgfb1. The pGL3-Tgfb1-Mut reporter plasmid was made by a PCR-directed linker scanning mutagenesis approach with Tgfb1-Mut forward (5'-GCCAAA GCTTAACTTTTGGATCTCAGAGAGCGCTCA-3') and reverse (5'-CTCCAAGCTTCTTAAATAGGGGAGCTAC TGCCA-3') primers with HindIII overhangs (underlined) as described by Gustin and Burk (30) . The plasmid p11x Gli1-BS, which contains Gli1-binding sites in front of a herpes simplex virus thymidine kinase (HSV-TK) promoter and firefly luciferase was used as a positive control for Shh activation (31) . All constructs were sequence verified. The plasmid pGL3 (Promega) was used as a negative control. The reference plasmid pRL-TK, containing the Renilla luciferase gene driven by the HSV-TK promoter, was co-transfected with reporter plasmids for normalization purposes. NIH-3T3 cells (ATCC) were seeded in 6-well plates the day before transfection. Cells were transfected with 1 μg reporter plasmid, 1 μg effector plasmid, and 10 ng reference plasmid using FuGene 6 transfection reagent (Roche Diagnostics) as indicated. Forty-eight hours after transfection, cells were lysed and reporter gene activity was determined using the Dual-Glo Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity. All reporter assay experiments were repeated at least three times, and transfections done in duplicate.
Results
Gene expression profiling revealed Tgfb1 as a candidate gene in Ptch1-associated RMS. To identify candidate genes involved in tumorigenesis of Ptch1-associated RMS, we screened for differentially expressed genes in 2 matched cases of RMS and SM tissue of Ptch1 neo67/+ mice using cDNA array technology. RNA was prepared from tumor and control tissues, 32 P-labeled and hybridized to cDNA arrays containing 588 known mouse genes. By comparing the specific hybridization patterns of both samples, we found 25 genes with striking differences in signal intensity (Fig. 1) . Genes with increased expression in RMS tissue included known RMS-associated genes (Igf2, Vil2, p21, p53, Itgb1), genes implicated in Tgf-ß signaling (Tgfb1, Ski, Igfbp3), as well as numerous genes coding for structural components of myogenic cells such as Myl4, Myl6, and Vim. In contrast, genes like cyclin G (Ccng) and transcription elongation factor S-II as well as genes encoding protein kinases (LIM-domain containing protein kinase, MAP kinase-activated protein kinase 2, mitogen-activated protein kinase 14) displayed reduced transcript levels in RMS tissue.
To verify the detected gene expression alterations we subsequently performed Northern blot analysis using specific DNA probes for the murine genes. Hybridization of the respective 32 P-labeled DNA probes to total RNA from RMS and SM revealed strong signals for Vim, Tgfb1, Igf2, Myl4, matrix metalloproteinase 14 (Mmp14), Myl6, inhibin α (Inha), prothymosin α (Ptma), Itgb1, Igfbp3, and glutathione peroxidase 3 (Gpx3) in tumor and weak signals in reference tissue, whereas the Ccng probe generated an inverse pattern (Fig. 2) . Interestingly, RMS tissue exhibited an additional shorter transcript for Tgfb1 compared to SM, which was strongly expressed only in the tumor.
P2 promoter of the murine Tgfb1 gene is not responsive to
Gli1. To determine whether the identified genes upregulated in Ptch1-associated RMS were direct downstream targets of hedgehog signaling, we exploited the fact that murine Gli is a sequence-specific DNA-binding protein that interacts with the motif GAACACCCA (32) . Among the genes verified by Northern blot analysis (see above), the Tgfb1 gene contained a putative Gli binding site with the 9-bp consensus sequence in the P2 promoter at position +250 upstream of the translational start site (Fig. 3A) . Interestingly, the human TGFB1 P2 promoter region contains the consensus sequence GACCAC CCA of the human GLI protein (33).
Since we found a significant increase in the expression of a shorter Tgfb1 transcript in the tumor (Fig. 2) , we wondered whether this expression could be induced through binding of Gli proteins to the P2 promoter of the Tgfb1 gene. Thus, we cloned the 5'-untranslated region (5'-UTR) of the murine Tgfb1 gene in front of the luciferase gene and additionally mutated the Gli binding site from GAACACCCA to GAAG CTTAA. The resulting two reporter plasmids were checked for responsiveness using luciferase assays in NIH-3T3 cells, since these cells were capable of promoting P2-dependent transcription (29) . We found that the entire 5'-UTR containing the wild-type Gli binding site (P2) was able to induce luciferase expression 6.5-fold (Fig. 3B ) compared to the empty control vector (pGL3). However, the mutated reporter construct (P2-Mut) induced luciferase expression in a similar way (7.2-fold), thus emphasizing that the Gli binding site is not necessary for the activation of the reporter in unstimulated NIH-3T3 cells. We then asked whether activation of hedgehog signaling could enhance the reporter activity and whether there is a difference between the wild-type and the mutated reporter. To question this, we co-transfected the murine Gli1 expression plasmid and the respective reporter plasmid into NIH-3T3 cells (Fig. 3C) . We detected no increase in wildtype and mutated reporter activity in Gli1 transfected cells compared to empty vector controls. To verify that the Gli1 effector is functional, we performed transfections using the murine Gli1 expression plasmid together with the 11xGli reporter, which resulted in a strong activation of luciferase activity. Thus, our data indicate that the Gli binding site found in the P2 promoter of Tgfb1 is not responsive to Gli1 and therefore might not be responsible for the P2-driven expression of the Tgfb1 transcript. We found that stimulation of murine C2C12 myoblasts with mouse Shh-N results in a strong Gli1 expression (Fig. 4A) . In sharp contrast, Tgfb1 expression was uniformly strong in unstimulated and stimulated cells. Since it is known that hedgehog signaling could be specifically inhibited by the plant alkaloid cyclopamine (34), we repeated the experiments in the presence of this inhibitory compound. As expected, Gli1 expression was blocked by the addition of cyclopamine, whereas Tgfb1 expression was unaffected by this treatment. These results demonstrate that Tgfb1 expression could not be induced by hedgehog signaling in myogenic cells, as described for fibroblasts (see above). Second, we wanted to ascertain whether Tgfb1 might be transcriptionally activated by a constitutively activated Shh signaling pathway by analyzing Tgfb1 expression in Ptch1 neo67/neo67 embryos by means of semi-quantitative RT-PCR. The homozygous loss of Ptch1 alleles resulted in a strong increase in Gli1 expression, which was used as a positive control for the induction of the pathway (Fig. 4B) . However, Tgfb1 expression was not elevated in Ptch1-deficient embryos, again indicating that Tgfb1 is not a target gene of hedgehog signaling.
Human tumor cells show strong expression of TGFB1 independent of GLI1. After demonstrating that Tgfb1 is highly expressed in Ptch1-associated RMS of the mouse and ruling out that Tgfb1 is a transcriptional target of an activated hedgehog pathway we wanted to see whether overexpression of Tgfb1 is a more common phenomenon in RMS than in hedgehog-dependent tumors. For this reason we decided to investigate human RMS cell lines for their expression of GLI1 and TGFB1 by Northern blot analysis. We found a strong GLI1 expression in the three cell lines RH-30, RMS-13, and RH-1, with RMS-13 exhibiting the most prominent expression (Fig. 5) . This is in line with the described amplification of GLI1 in RMS-13 cells (35) . However, monitoring TGFB1 expression we found high transcript levels throughout all 4 RMS cell lines, with no consistent co-expression of GLI1 and TGFB1. While the extremely high expression of GLI1 in RMS-13 cells occurred together with a relatively weak expression of TGFB1 on the one hand, RD cells expressed hardly any GLI1 and very high levels of TGFB1 on the other hand. These results clearly demonstrate that the dramatically high expression of TGFB1 is specifically associated with RMS, but independent of hedgehog signaling. 
Discussion
RMS is an aggressive soft-tissue tumor affecting mainly children and young adults (4) . Since the development of new therapies has been hampered by the lack of knowledge about the exact molecular basis of this pediatric tumor, RMS is still associated with a high mortality. Thus, identification of novel genes implicated in the genesis of RMS is of uttermost importance. In view of the fact that human RMS are relatively rare and that RMS of the Ptch1 knockout mouse model mirror the histological and molecular features of human RMS (12) (13) (14) , we have analyzed variations of gene expression in these murine RMS by using the cDNA array technology.
A significant number of the 25 candidates depicted in our study (e.g., Igf2, Vil2, p53, p21, Vim, Itgb1, Myl4) has been already described in earlier studies to be implicated in the formation and progression of RMS. The most prominent candidate gene identified codes for the survival factor IGF2, which has been known for years to be highly expressed in human RMS (36, 37) . In vitro assays have moreover shown that IGF2 can act as an autocrine growth factor in RMS cells, and also as a promoter of cellular motility (36) . Interestingly, RMS of Ptch1 neo67/+ mice mirror the high Igf2 transcript levels found in human RMS and develop only in the presence of functional Igf2, as revealed by a genetic double knockout (Ptch1 neo67/+ /Igf2 +/-) approach (11, 12) . Another appealing gene we detected was Vil2 encoding the membrane-cytoskeletal linking protein ezrin. This gene has been found heavily overexpressed in metastatic tumors of the hepatocyte growth factor-transgenic and Ink4a/Arf-deficient double-mutant mice, which develop highly invasive RMS by the age of four months (38) . Moreover, this study demonstrated a strong correlation of VIL2 expression with metastasis in human RMS. Other candidates like the genes coding for the cell-cycle regulators p53 and p21 have previously been described to be strongly expressed in murine and human RMS, however, correlations with tumor subtype and prognosis were not significant (14, 39) . Additionally, human RMS has been identified to be nearly consistently positive for vimentin and integrin ß by means of immunohistochemistry (9, 10, 40) . Recent work has reported a high expression of the human MYL4 gene (homologous to the murine Myl4 gene) in alveolar RMS using cDNA microarrays (41, 42) . In light of these results it is safe to predict that analyzing the transcriptional signature of murine Ptch1-associated RMS is a valuable approach for the rapid identification of important genes involved in the genesis of human RMS.
The most remarkable finding of our study was the identification of an aberrantly high expression of the Tgfb1 gene in Ptch1-associated RMS compared to normal SM. Even though strong expression of TGFB1 has been described earlier in human RMS and the ERMS cell line RD (43, 44) , we show here that the elevated Tgfb1 expression originates from a second Tgfb1 transcript, which is solely expressed in the tumor. It has been reported that the major murine Tgfb1 mRNA species appears as a 2.5 kb band on Northern blots (45) . In addition, a smaller mRNA of about 1.9 kb has been detected in the murine sarcoma virus-transformed 3T3 line 3B11-1C and the monocytic line pU5-1.8 (45) as well as murine male germ cells (46) . Several lines of evidence indicate that the shorter transcript of 1.9 kb is also induced in injured tissues, such as the infarcted heart (47), carbon tetrachlorideexposed liver (48, 49) , and carcinogen-treated skin (50) . Since it has been speculated that the second promoter region in the Tgfb1 gene might be involved in regulating the synthesis of this shorter transcript (51) and since we found a putative Gli binding site within this region, we reasoned whether the tumor-specific transcript found in RMS could be induced by binding of Gli to the P2 promoter of the Tgfb1 gene. To verify this hypothesis, we checked for Tgfb1 expression by following three different modes of active hedgehog signaling in three different cell/tissue types: transient Gli1 transfection in murine NIH-3T3 cells, Shh-N stimulation in murine C2C12 myoblasts, and constitutively active hedgehog signaling in Ptch1-deficient mouse embryos. However, our results entirely argue against a direct induction of a second Tgfb1 transcript by hedgehog signaling. We rather assume that Tgfb1 overexpression is a common phenomenon in RMS independent of hedgehog signaling, since we have detected high TGFB1 RNA levels in four human RMS cell lines independently of their GLI1 expression status.
This assumption is substantiated by the finding that Tgfb1 has differentiation inhibiting and growth inducing effects on myogenic cells. TGF-ß family members function as potent inhibitors of terminal muscle differentiation (52, 53) by silencing the transcriptional activation of MyoD and myogenin, two members of the bHLH family (54, 55) . This inhibition of differentiation by TGFB1 persists even in nonmuscle cell lines engineered to ectopically express members of the bHLH family (54) (55) (56) . Recent studies have described that overproduction of TGFB1 and an autocrine TGFB1 loop is responsible for the growth of RMS (57) and that TGFB1 exhibits a growth-inducing effect in human airway smooth muscle cells through a mechanism that requires TGFBP3 expression (58) . Interestingly, Tgfb1 and Igfbp3 were concomitantly overexpressed in Ptch1-asssociated RMS of our study.
Taken together these data propose an important regulatory function of Tgfb1 on cell growth and differentiation during the development of RMS, which however, is independent of an activated hedgehog signaling pathway.
